Applicability of a novel immunoassay based on surface plasmon resonance for the diagnosis of Chagas disease

Luz, João Gabriel Guimarães; Souto, Dênio Emanuel Pires; Machado-Assis, Girley F.; Lana, Marta de; Luz, Rita C. S.; Martins‐Filho, Olindo Assis; Damos, Flávio Santos; Martins, Helen Rodrigues

doi:10.1016/j.cca.2015.12.025

Cited by 15 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, laboratory methods are employed to diagnose CD, depending on the patients’ phase of infection, some methods being more convenient than others [ 28 ]. During the acute phase of CD, a large number of parasites are present in the peripheral blood and can be diagnosed by a parasitological test such as a direct microscopical observation of fresh blood and by one of several polymerase chain reaction (PCR) techniques.…”

Section: Current Detection Technologies and Their Limitationsmentioning

confidence: 99%

“…These tests present several limitations such as (i) cross-reactivity with other parasites; (ii) a lack of 100% sensitivity (sensitivity and specificity represent parameters of great clinical relevance in the evaluation of a diagnostic test. Sensitivity indicates the total absence of false-negative results, while the specificity indicates a false-positive rate [ 28 ]); (iii) the need for dedicated laboratories to conduct the tests; and (iv) the requirement of long analysis times to obtain the results. IHA test results can be obtained in about two hours, whereas IIF results can be obtained after numerous steps in two hours and ELISA takes several hours to carry out, including prior sensitization of microplates with T. cruzi antigens for about 12 h [ 6 ].…”

Section: Current Detection Technologies and Their Limitationsmentioning

confidence: 99%

“…They obtained the parameter related to the presence of antibodies anti- T. cruzi found in human serum in approximately 20 min. In 2016, this same group observed that the immunoassay they conducted discriminated CD from other infectious diseases with a higher percentage of accuracy compared to ELISA and also presented a higher sensitivity—of 100%—compared to other diagnostic methods, such as PCR, which has a sensitivity of 90% and a satisfactory specificity of 97.2% [ 28 ]. These facts, in our opinion, prove the SPR technique to be very promising for CD diagnosis.…”

Section: Biosensing Research Efforts For Chagas Diagnosismentioning

confidence: 99%

See 2 more Smart Citations

Biosensors to Diagnose Chagas Disease: A Brief Review

Rocha-Gaso

Villarreal-Gómez

Beyssen

et al. 2017

Sensors

View full text Add to dashboard Cite

Chagas disease (CD), which mostly affects those living in deprived areas, has become one of Latin America’s main public health problems. Effective prevention of the disease requires early diagnosis, initiation of therapy, and regular blood monitoring of the infected individual. However, the majority of the Trypanosoma cruzi infections go undiagnosed because of mild symptoms, limited access to medical attention and to a high variability in the sensitivity and specificity of diagnostic tests. Consequently, more affordable and accessible detection technologies capable of providing early diagnosis and T. cruzi load measurements in settings where CD is most prevalent are needed to enable enhanced intervention strategies. This work analyzes the potential contribution of biosensing technologies, reviewing examples that have been tested and contrasted with traditional methods, both serological and parasitological (i.e., molecular detection by PCR), and discusses some emerging biosensing technologies that have been applied for this public health issue. Even if biosensing technologies still require further research efforts to develop portable systems, we arrive at the conclusion that biosensors could improve the accuracy of CD diagnosis and the follow-up of patients’ treatments in terms of the rapidity of results, small sample volume, high integration, ease of use, real-time and low cost detection when compared with current conventional technologies.

show abstract

Section: Current Detection Technologies and Their Limitationsmentioning

confidence: 99%

Section: Current Detection Technologies and Their Limitationsmentioning

confidence: 99%

Section: Biosensing Research Efforts For Chagas Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Biosensors to Diagnose Chagas Disease: A Brief Review

Rocha-Gaso

Villarreal-Gómez

Beyssen

et al. 2017

Sensors

View full text Add to dashboard Cite

show abstract

“…Because no standardized reference test is commercially available, the World Health Organization advises the use of two distinct techniques for CD diagnosis (7) and the Brazilian Health Ministry recommends 2 serological methods involving distinct antigen preparations, both of which must be performed concomitantly (6). Next-generation diagnostic platforms have improved the accuracy of CD diagnosis by using different T. cruzi-specific recombinant proteins in a variety of detection systems, such as chemiluminescence (8), surface plasmon resonance (9,10), and bead-based technologies, including cytometry bead arrays (11) and liquid microarrays (LMAs) (12).…”

mentioning

confidence: 99%

Performance Assessment of a Trypanosoma cruzi Chimeric Antigen in Multiplex Liquid Microarray Assays

et al. 2017

View full text Add to dashboard Cite

Diagnosing chronic Chagas disease (CD) requires antibody-antigen detection methods, which are traditionally based on enzymatic assay techniques whose performance depend on the type and quality of antigen used. Previously, 4 recombinant chimeric proteins from the Instituto de Biologia Molecular do Paraná (IBMP-8.1 to 8.4) comprising immuno-dominant regions of diverse antigens showed excellent diagnostic performance in enzyme-linked immunosorbent assays. Considering that next-generation platforms offer improved CD diagnostic accuracy with different-specific recombinant antigens, we assessed the performance of these chimeras in liquid microarrays (LMAs). The chimeric proteins were expressed in and purified by chromatography. Sera from 653 chagasic and 680 healthy individuals were used to assess the performance of these chimeras in detecting specific anti- antibodies. Accuracies ranged from 98.1 to 99.3%, and diagnostic odds ratio values were 3,548 for IBMP-8.3, 4,826 for IBMP-8.1, 7,882 for IBMP-8.2, and 25,000 for IBMP-8.4. A separate sera bank (851 samples) was employed to assess cross-reactivity with other tropical diseases. , a pathogen with high similarity to, showed cross-reactivity rates ranging from 0 to 2.17%. Inconclusive results were negligible (0 to 0.71%). Bland-Altman and Deming regression analysis based on 200 randomly selected CD-positive and negative samples demonstrated interchangeability with respect to CD diagnostic performance in both singleplex and multiplex assays. Our results suggested that these chimeras can potentially replace antigens currently used in commercially available assay kits. Moreover, the use of multiplex platforms, such as LMA assays employing 2 or more IBMP antigens, would abrogate the need for 2 different testing techniques when diagnosing CD.

show abstract

“…Exames laboratoriais são utilizados no diagnóstico da doença de Chagas, e as diferentes metodologias podem ser melhores empregadas de acordo com a fase da infecção (LUZ et al, 2016). Na fase aguda da doença é encontrada uma alta taxa de parasito no sangue periférico, dessa forma, o diagnóstico laboratorial pode ser feito por testes parasitológicos, como microscopia direta com a observação de parasito em sangue fresco e por Reação em Cadeia da Polimerase (PCR).…”

Section: Diagnóstico Da Doença De Chagasunclassified

Propriedades biológicas das proteínas Galectina-3 e rP21 na infecção por Trypanosoma cruzi in vitro e in vivo

Silva¹

View full text Add to dashboard Cite

Applicability of a novel immunoassay based on surface plasmon resonance for the diagnosis of Chagas disease

Cited by 15 publications

References 32 publications

Biosensors to Diagnose Chagas Disease: A Brief Review

Biosensors to Diagnose Chagas Disease: A Brief Review

Performance Assessment of a Trypanosoma cruzi Chimeric Antigen in Multiplex Liquid Microarray Assays

Propriedades biológicas das proteínas Galectina-3 e rP21 na infecção por Trypanosoma cruzi in vitro e in vivo

Contact Info

Product

Resources

About